GlassScriptPhysician profile
Stephen Michael Hix
NPI 1477224392
$5,284.06
in general payments reported to CMS, 2019-2025
51 companies · $1,622 in 2025
The $1,622 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.94 · 2022: $1,319 · 2023: $1,008 · 2024: $1,313 · 2025: $1,622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,943.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $920.67 | 2022-2025 | Entyvio, Eohilia, Fruzaqla |
| Astrazeneca Pharmaceuticals LP | $470.08 | 2022-2025 | Lynparza, Enhertu |
| Madrigal Pharmaceuticals | $396.39 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $275.24 | 2022-2025 | |
| Abbvie INC. | $274.17 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $233.95 | 2022-2025 | Dupixent, Libtayo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $186.76 | 2022-2024 | Trulance |
| Janssen Biotech, INC. | $185.19 | 2022-2025 | Tremfya, Stelara |
| Merck Sharp & Dohme LLC | $162.22 | 2022-2025 | Keytruda, Keytruda Qlex |
| Shield Therapeutics INC | $159.29 | 2025 | |
| Ironwood Pharmaceuticals, INC | $117.69 | 2022-2024 | Linzess |
| Lilly USA, LLC | $117.64 | 2022-2025 | Retevmo, Verzenio, Jaypirca |
| Novartis Pharmaceuticals Corporation | $106.87 | 2022-2025 | |
| Qol Medical, LLC | $106.01 | 2022-2024 | Sucraid, Sucraid |
| Genentech USA, INC. | $103.74 | 2024-2025 | Polivy, Tecentriq Hybreza, Lunsumio |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $103.59 | 2024-2025 | Vowst, Zenpep |
| Ardelyx, INC. | $96.67 | 2022-2025 | Ibsrela |
| Celgene Corporation | $95.13 | 2022-2024 | Zeposia, Opdualag |
| Daiichi Sankyo INC. | $89.87 | 2023-2025 | Enhertu |
| Janssen Scientific Affairs, LLC | $89.48 | 2022 | |
| Phathom Pharmaceuticals, INC. | $88.24 | 2024-2025 | Voquezna |
| Tersera Therapeutics LLC | $77.00 | 2023-2025 | Zoladex, Quzyttir |
| Alexion Pharmaceuticals, INC. | $74.90 | 2023-2025 | Ultomiris |
| Seagen INC. | $71.62 | 2022-2023 | Tukysa, Adcetris |
| Incyte Corporation | $68.35 | 2024-2025 | Jakafi |
| Davol INC. | $50.98 | 2022 | |
| Sobi, INC | $50.10 | 2024-2025 | |
| Stemline Therapeutics INC. | $47.64 | 2023 | Orserdu |
| Smith+Nephew, INC. | $40.25 | 2021-2022 | |
| Taiho Oncology, INC. | $38.47 | 2023 | |
| Aveo Pharmaceuticals, INC. | $29.62 | 2023 | Fotivda |
| Blueprint Medicines Corporation | $27.99 | 2024 | Ayvakit |
| Agios Pharmaceuticals, INC. | $24.53 | 2024 | |
| Sun Pharmaceutical Industries INC. | $23.35 | 2022 | |
| Celltrion USA INC. | $23.04 | 2025 | Vegzelma |
| Ipsen Biopharmaceuticals, INC | $20.63 | 2024 | Iqirvo |
| Amgen INC. | $20.05 | 2023 | Amjevita, Avsola |
| Rigel Pharmaceuticals, INC. | $17.94 | 2023 | Tavalisse, Rezlidhia |
| Mirati Therapeutics, INC. | $17.86 | 2024 | Krazati |
| Eisai INC. | $17.51 | 2022 | |
| Medtronic, INC. | $16.36 | 2024 | Interstim |
| Melinta Therapeutics, LLC | $16.08 | 2022 | |
| Geron Corporation | $15.60 | 2025 | Rytelo |
| Pacira Pharmaceuticals Incorporated | $14.99 | 2023 | Exparel |
| Cti Biopharma Corp. | $14.90 | 2022 | |
| Novo Nordisk INC | $14.85 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $14.79 | 2022 | |
| G1 Therapeutics, INC. | $14.28 | 2022 | |
| Myriad Genetic Laboratories, INC. | $14.17 | 2025 | Endopredict |
| Inari Medical, INC. | $13.96 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Intercept Pharmaceuticals, INC. | $13.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Hix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.